The role of HE4 in ovarian cancer follow-up: A review

Elisa Piovano, Lorenza Attamante, Chiara Macchi, Camilla Cavallero, Cesare Romagnolo, Tiziano Maggino, Fabio Landoni, Angiolo Gadducci, Enrico Sartori, Massimo Gion, Paolo Zola

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: The aim of this review was to analyze the state of the art about HE4 and follow-up in patients treated for ovarian cancer. Methods: A literature search was conducted in the MEDLINE database using the key words "HE4" and "ovarian cancer" and "recurrence" or "relapse" or "follow up." Results: Seven of 28 clinical studies were selected. Four studies were prospective, and all of them were based on a small number of patients (8Y73 women). A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis, thus suggesting the need of a closer follow-up. Moreover, HE4 showed better sensibility and specificity in the diagnosis of ovarian cancer recurrence with respect to CA-125, being also an earlier indicator of the relapse with a lead time of 5 to 8 months. HE4 showed a better performance in this setting if performed in association with other markers (CA-125, CA-72.4). HE4 seems to be an independent predictive factor for the surgical outcome at secondary cytoreductive surgery and to maintain its prognostic role even after the recurrence. Conclusions: These preliminary data start to suggest a superiority of HE4 over CA-125 in the detection of ovarian cancer recurrence. Moreover, the prognostic role of HE4 could help clinicians to personalize the follow-up program, whereas its predictive role could be useful to plan the treatment of the relapse. The role of HE4 in ovarian cancer follow-up deserves to be further investigated in prospective randomized multicentric studies.

Original languageEnglish
Pages (from-to)1359-1365
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number8
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Ovarian Neoplasms
Recurrence
MEDLINE
Databases
Prospective Studies
Therapeutics

Keywords

  • CA-125
  • Follow-up
  • HE4
  • Ovarian cancer
  • Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Medicine(all)

Cite this

Piovano, E., Attamante, L., Macchi, C., Cavallero, C., Romagnolo, C., Maggino, T., ... Zola, P. (2014). The role of HE4 in ovarian cancer follow-up: A review. International Journal of Gynecological Cancer, 24(8), 1359-1365. https://doi.org/10.1097/IGC.0000000000000218

The role of HE4 in ovarian cancer follow-up : A review. / Piovano, Elisa; Attamante, Lorenza; Macchi, Chiara; Cavallero, Camilla; Romagnolo, Cesare; Maggino, Tiziano; Landoni, Fabio; Gadducci, Angiolo; Sartori, Enrico; Gion, Massimo; Zola, Paolo.

In: International Journal of Gynecological Cancer, Vol. 24, No. 8, 01.10.2014, p. 1359-1365.

Research output: Contribution to journalArticle

Piovano, E, Attamante, L, Macchi, C, Cavallero, C, Romagnolo, C, Maggino, T, Landoni, F, Gadducci, A, Sartori, E, Gion, M & Zola, P 2014, 'The role of HE4 in ovarian cancer follow-up: A review', International Journal of Gynecological Cancer, vol. 24, no. 8, pp. 1359-1365. https://doi.org/10.1097/IGC.0000000000000218
Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T et al. The role of HE4 in ovarian cancer follow-up: A review. International Journal of Gynecological Cancer. 2014 Oct 1;24(8):1359-1365. https://doi.org/10.1097/IGC.0000000000000218
Piovano, Elisa ; Attamante, Lorenza ; Macchi, Chiara ; Cavallero, Camilla ; Romagnolo, Cesare ; Maggino, Tiziano ; Landoni, Fabio ; Gadducci, Angiolo ; Sartori, Enrico ; Gion, Massimo ; Zola, Paolo. / The role of HE4 in ovarian cancer follow-up : A review. In: International Journal of Gynecological Cancer. 2014 ; Vol. 24, No. 8. pp. 1359-1365.
@article{8a9e0580e49f4981904b919d49eb6d6a,
title = "The role of HE4 in ovarian cancer follow-up: A review",
abstract = "Objective: The aim of this review was to analyze the state of the art about HE4 and follow-up in patients treated for ovarian cancer. Methods: A literature search was conducted in the MEDLINE database using the key words {"}HE4{"} and {"}ovarian cancer{"} and {"}recurrence{"} or {"}relapse{"} or {"}follow up.{"} Results: Seven of 28 clinical studies were selected. Four studies were prospective, and all of them were based on a small number of patients (8Y73 women). A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis, thus suggesting the need of a closer follow-up. Moreover, HE4 showed better sensibility and specificity in the diagnosis of ovarian cancer recurrence with respect to CA-125, being also an earlier indicator of the relapse with a lead time of 5 to 8 months. HE4 showed a better performance in this setting if performed in association with other markers (CA-125, CA-72.4). HE4 seems to be an independent predictive factor for the surgical outcome at secondary cytoreductive surgery and to maintain its prognostic role even after the recurrence. Conclusions: These preliminary data start to suggest a superiority of HE4 over CA-125 in the detection of ovarian cancer recurrence. Moreover, the prognostic role of HE4 could help clinicians to personalize the follow-up program, whereas its predictive role could be useful to plan the treatment of the relapse. The role of HE4 in ovarian cancer follow-up deserves to be further investigated in prospective randomized multicentric studies.",
keywords = "CA-125, Follow-up, HE4, Ovarian cancer, Recurrence",
author = "Elisa Piovano and Lorenza Attamante and Chiara Macchi and Camilla Cavallero and Cesare Romagnolo and Tiziano Maggino and Fabio Landoni and Angiolo Gadducci and Enrico Sartori and Massimo Gion and Paolo Zola",
year = "2014",
month = "10",
day = "1",
doi = "10.1097/IGC.0000000000000218",
language = "English",
volume = "24",
pages = "1359--1365",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - The role of HE4 in ovarian cancer follow-up

T2 - A review

AU - Piovano, Elisa

AU - Attamante, Lorenza

AU - Macchi, Chiara

AU - Cavallero, Camilla

AU - Romagnolo, Cesare

AU - Maggino, Tiziano

AU - Landoni, Fabio

AU - Gadducci, Angiolo

AU - Sartori, Enrico

AU - Gion, Massimo

AU - Zola, Paolo

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Objective: The aim of this review was to analyze the state of the art about HE4 and follow-up in patients treated for ovarian cancer. Methods: A literature search was conducted in the MEDLINE database using the key words "HE4" and "ovarian cancer" and "recurrence" or "relapse" or "follow up." Results: Seven of 28 clinical studies were selected. Four studies were prospective, and all of them were based on a small number of patients (8Y73 women). A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis, thus suggesting the need of a closer follow-up. Moreover, HE4 showed better sensibility and specificity in the diagnosis of ovarian cancer recurrence with respect to CA-125, being also an earlier indicator of the relapse with a lead time of 5 to 8 months. HE4 showed a better performance in this setting if performed in association with other markers (CA-125, CA-72.4). HE4 seems to be an independent predictive factor for the surgical outcome at secondary cytoreductive surgery and to maintain its prognostic role even after the recurrence. Conclusions: These preliminary data start to suggest a superiority of HE4 over CA-125 in the detection of ovarian cancer recurrence. Moreover, the prognostic role of HE4 could help clinicians to personalize the follow-up program, whereas its predictive role could be useful to plan the treatment of the relapse. The role of HE4 in ovarian cancer follow-up deserves to be further investigated in prospective randomized multicentric studies.

AB - Objective: The aim of this review was to analyze the state of the art about HE4 and follow-up in patients treated for ovarian cancer. Methods: A literature search was conducted in the MEDLINE database using the key words "HE4" and "ovarian cancer" and "recurrence" or "relapse" or "follow up." Results: Seven of 28 clinical studies were selected. Four studies were prospective, and all of them were based on a small number of patients (8Y73 women). A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis, thus suggesting the need of a closer follow-up. Moreover, HE4 showed better sensibility and specificity in the diagnosis of ovarian cancer recurrence with respect to CA-125, being also an earlier indicator of the relapse with a lead time of 5 to 8 months. HE4 showed a better performance in this setting if performed in association with other markers (CA-125, CA-72.4). HE4 seems to be an independent predictive factor for the surgical outcome at secondary cytoreductive surgery and to maintain its prognostic role even after the recurrence. Conclusions: These preliminary data start to suggest a superiority of HE4 over CA-125 in the detection of ovarian cancer recurrence. Moreover, the prognostic role of HE4 could help clinicians to personalize the follow-up program, whereas its predictive role could be useful to plan the treatment of the relapse. The role of HE4 in ovarian cancer follow-up deserves to be further investigated in prospective randomized multicentric studies.

KW - CA-125

KW - Follow-up

KW - HE4

KW - Ovarian cancer

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84925654957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925654957&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000218

DO - 10.1097/IGC.0000000000000218

M3 - Article

C2 - 25054447

AN - SCOPUS:84925654957

VL - 24

SP - 1359

EP - 1365

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 8

ER -